Magazine Article | September 1, 2020

Companies To Watch: CalciMedica

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

CalciMedica

Long-term planning for pancreatitis, quickly pivoting for COVID pneumonia

SNAPSHOT

CalciMedica has been developing a new class of anti-inflammatory drugs, calcium release-activated calcium (CRAC) channel blockers, with the lead indications for treating acute pancreatitis and viral pneumonia now in Phase 2 trials for its compound, Auxora, an injectable emulsion. Recently, the company discovered the same drug may have a large impact on systemic inflammatory response syndrome (SIRS), the hyperimmunity associated with viral pneumonia, a common comorbidity and comortality condition in COVID-19 disease. Hence, it now has a Phase 3 trial underway with Auxora targeting severe COVID-19 pneumonia.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: